Aryl Hydrocarbon Receptor Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR Pipeline Review, H1 2018
Summary
Aryl Hydrocarbon Receptor Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR Aryl hydrocarbon receptor is a protein encoded by the AHR gene. It mediates biochemical and toxic effects of halogenated aromatic hydrocarbons. It involved in cellcycle regulation. It plays an important role in the development and maturation of many tissues. It regulates the circadian clock by inhibiting the basal and circadian expression of the core circadian component PER1.
Aryl Hydrocarbon Receptor Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Preclinical and Discovery stages are 1, 9 and 2 respectively.
Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Metabolic Disorders, Central Nervous System and Gastrointestinal which include indications Breast Cancer, Multiple Sclerosis, Type 1 Diabetes Juvenile Diabetes, AndrogenSensitive Prostate Cancer, Celiac Disease, Chronic Myelocytic Leukemia CML, Chronic Myeloid Leukemia, Graft Versus Host Disease GVHD, Hepatocellular Carcinoma, Inflammatory Bowel Disease, Myasthenia Gravis, Obesity, Ovarian Cancer, Rheumatoid Arthritis and Solid Tumor.
The latest report Aryl Hydrocarbon Receptor Pipeline Review, H1 2018, outlays comprehensive information on the Aryl Hydrocarbon Receptor Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. It also reviews key players involved in Aryl Hydrocarbon Receptor Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Aryl Hydrocarbon Receptor Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR
The report reviews Aryl Hydrocarbon Receptor Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Aryl Hydrocarbon Receptor Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR targeted therapeutics and enlists all their major and minor projects
The report assesses Aryl Hydrocarbon Receptor Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Aryl Hydrocarbon Receptor Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Aryl Hydrocarbon Receptor Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Aryl Hydrocarbon Receptor Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope